BidaskClub Lowers ANI Pharmaceuticals (NASDAQ:ANIP) to Hold
Several other equities research analysts also recently issued reports on the stock. ValuEngine raised shares of Xylem from a hold rating to a buy rating in a research report on Friday, June 21st. Canaccord Genuity downgraded shares of Magellan Aerospace from a buy rating to a hold rating and lowered their price objective for the stock from C$21.00 to C$20.00 in a research report on Monday, May 13th. Raymond James reissued a buy rating on shares of Canadian Natural Resources in a research report on Friday, May 10th. Cantor Fitzgerald reissued a buy rating and set a $27.00 price objective on shares of Spero Therapeutics in a research report on Thursday, May 9th. Finally, TheStreet raised shares of TerraForm Power from a c rating to a b- rating in a research report on Tuesday, March 19th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $84.50.
Shares of NASDAQ:ANIP opened at $81.36 on Thursday. ANI Pharmaceuticals has a 52 week low of $36.92 and a 52 week high of $84.10. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.92 and a quick ratio of 0.67. The company has a market capitalization of $980.06 million, a P/E ratio of 17.38 and a beta of 2.25. The firm has a 50 day moving average price of $75.21.
In other ANI Pharmaceuticals news, Director David Nash bought 1,445 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, May 24th. The stock was acquired at an average price of $68.76 per share, for a total transaction of $99,358.20. Following the completion of the acquisition, the director now owns 5,236 shares of the company’s stock, valued at approximately $360,027.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Arthur Przybyl sold 30,000 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $70.07, for a total transaction of $2,102,100.00. Following the transaction, the insider now owns 222,994 shares of the company’s stock, valued at approximately $15,625,189.58. The disclosure for this sale can be found here. Insiders have sold 50,911 shares of company stock valued at $3,585,114 in the last three months. 24.70% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. First Trust Advisors LP boosted its holdings in ANI Pharmaceuticals by 1.2% during the first quarter. First Trust Advisors LP now owns 15,122 shares of the specialty pharmaceutical company’s stock worth $1,067,000 after purchasing an additional 179 shares during the last quarter. Texas Permanent School Fund lifted its stake in ANI Pharmaceuticals by 3.8% in the first quarter. Texas Permanent School Fund now owns 5,633 shares of the specialty pharmaceutical company’s stock valued at $397,000 after acquiring an additional 206 shares during the last quarter. Comerica Bank lifted its stake in ANI Pharmaceuticals by 3.1% in the first quarter. Comerica Bank now owns 8,239 shares of the specialty pharmaceutical company’s stock valued at $570,000 after acquiring an additional 248 shares during the last quarter. THB Asset Management lifted its stake in ANI Pharmaceuticals by 1.1% in the first quarter. THB Asset Management now owns 25,431 shares of the specialty pharmaceutical company’s stock valued at $1,793,000 after acquiring an additional 275 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in ANI Pharmaceuticals by 0.8% in the fourth quarter. Principal Financial Group Inc. now owns 67,326 shares of the specialty pharmaceutical company’s stock valued at $3,031,000 after acquiring an additional 529 shares during the last quarter. Institutional investors and hedge funds own 63.92% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
See Also: What is a Fiduciary?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.